Get in Touch

Start Referring Patients Today. Prevent AMD vision loss with remote monitoring. Fill out the form below to get started.
Doctor Ophthalmic Staff
Retina Specialist Comprehensive Ophthalmologist Optometrist
Retina Specialty Comprehensive Ophthalmology Optometry Technician Lead Technician Scribe Front Office Management Unknown
By Email By Phone
Internet Print Word of Mouth Other

Comments

Latest News
Alerts

After a ForeseeHome Alert: When Should a Patient Be Seen?

October 2021


A question the Notal Vision Monitoring Center Medical Directors often receive is “How soon after a ForeseeHome alert do patients need to be seen?” The simple answer is that the best course of action after an alert is up to the referring doctor, as only they know both the patient and the clinical situation. However, we can refer to what the HOME study1 included about
seeing a patient after an alert notification. In the HOME study, a visit was required to the study office within 72 hours after the clinic received the alert notification. There are several reasons why 72 hours was chosen:

  • If the alert is due to a conversion to neovascular AMD, there is certainly some urgency. Many studies show that the better the visual acuity is at the start of treatment, the better it will be long-term; patients with very poor visual acuity at the start of treatment will not regain functional vision after treatment.
  • It allows time for the patient to adjust their schedule and arrange transportation to the clinic for their appointment.
  • It gives the clinic time to bring the patient in for evaluation and accounts for weekends when the clinic may be closed.

The Notal Vision Monitoring Center, provider of the ForeseeHome AMD Monitoring Program, is proud to support the care that clinicians give to their dry intermediate AMD patients to help preserve their vision and quality of life.

Questions for the Notal Vision Monitoring Center Medical Directors? Let us know.

Email Us

References

1. Chew EY, Clemons TE, Bressler SB, et al; AREDS2-HOME Study Research Group. Randomized trial of a
home monitoring system for early detection of choroidal neovascularization home monitoring of the
Eye (HOME) study. Ophthalmology. 2014;121(2):535-544.

Related News

View Latest News
View Latest News